October 23, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-3561
| Re: | Progenies Pharmaceuticals, Inc. (the "Company") - Request for Acceleration |
| Registration Statement on Form S-3 Filed October 12, 2018 (File No. 333-227805) |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby join the Company's request for acceleration of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:30 p.m. Eastern Time on October 24, 2018, or as soon thereafter as is practicable.
|
|
| |
| Very truly yours, | |||
| CANTOR FITZGERALD & CO. | |||
|
|
|
|
|
|
|
|
| By: | /s/ Mark Kaplan |
|
| Name: | Mark Kaplan |
|
| Title: | Global COO |
|
